Revenue
2014
2015
2018
2019
Sigyn Therapeutics, Inc. (SIGY)
Price—Loading quote
Net income
2014
2015
2018
2019
2020
2021
2023
2024
Free cash flow
2014
2015
2018
2021
Total cash / debt
CashTotal debt
2014
2015
2018
2019
2020
2021
2023
2024
Financial statements
| 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $143,322 | $28,348 | $29,207 | $43,154 |
| Gross profit | — | — | — | — | $107,657 | $18,636 | $19,277 | $17,904 |
| Research & development | $773,279 | $798,165 | $734,014 | $419,362 | — | — | — | — |
| Operating expenses | $2.5M | $2.5M | $2.0M | $916,434 | $625,615 | $1.0M | $2.3M | $405,448 |
| Operating income | −$2.5M | −$2.5M | −$2.0M | −$916,434 | −$517,958 | −$1.0M | −$2.3M | −$387,544 |
| EBITDAderived | — | −$2.4M | −$2.0M | −$905,134 | — | — | — | — |
| Net income | −$3.3M | −$4.1M | −$3.0M | −$1.3M | −$3.1M | −$2.6M | −$2.7M | −$387,544 |
| Basic EPSper diluted share | -$2.51 | -$3.77 | -$0.08 | -$0.17 | -$0.04 | -$0.04 | -$0.09 | -$0.01 |
| Diluted EPSper diluted share | -$2.51 | -$3.77 | -$0.08 | -$0.17 | -$0.04 | -$0.04 | -$0.09 | -$0.01 |